Literature DB >> 19578865

Toll like receptor agonists augment HPV 11 E7-specific T cell responses by modulating monocyte-derived dendritic cells.

Xian-Zhen Chen1, Xiao-Hong Mao, Ke-Jian Zhu, Na Jin, Jun Ye, Jian-Ping Cen, Qiang Zhou, Hao Cheng.   

Abstract

Impaired local cellular immunity is one of the mechanisms responsible for condyloma acuminatum (CA) recurrence. The activation of dendritic cells (DCs) is important in vaccine development. We investigated the effect of different toll like receptor (TLR) agonists including LPS (TLR4 agonist), polyinosinic acid-polycytidylic acid (PIC, TLR3 agonist), CpG oligonucleotide (TLR9 agonist), and imiquimod (TLR7 agonist) on human monocyte-derived dendritic cells (mdDCs) loading of human papillomavirus (HPV) type 11 E7 epitope. As a result, we found that mdDCs loading HLA-A*0201-restricted HPV 11 E7 CTL epitope peptide could respond to the TLR agonists, especially LPS and PIC. This was characterized by an enhanced expression of CD40, CD80, CD86, CD83 and HLA-DR, and a high level of IL-12 production. TLR agonists, especially PIC, enhanced the ability of E7-loaded mdDCs to induce IFN-gamma-secretion CD4(+) naïve T cells. Moreover, E7-loaded mdDCs exposed to TLR agonists augmented autologous T cell responses including effector cytokines production and specific cytotoxic T lymphocyte (CTL) responses. In addition, the inhibitory effect of IL-10 on mdDCs maturation could be partially restored by LPS, PIC or imiquimod. Taken together, these results demonstrate that TLR agonists promoted the maturation of E7-loaded mdDCs and their ability to induce T help type 1 polarization and augment E7-specific T cell responses. These data also indicated that TLR3/4 agonists might be effective adjuvants of mdDC-based vaccines against CA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19578865     DOI: 10.1007/s00403-009-0976-0

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  8 in total

Review 1.  Immunogenicity, safety and tolerability of intradermal influenza vaccines.

Authors:  Ivan F N Hung; Kwok-Yung Yuen
Journal:  Hum Vaccin Immunother       Date:  2017-07-06       Impact factor: 3.452

2.  Study of the expression of toll-like receptors in different histological types of colorectal polyps and their relationship with colorectal cancer.

Authors:  Noemí Eiró; Lucía González; Luis O González; Alejandro Andicoechea; María Fernández-Díaz; Antonio Altadill; Francisco J Vizoso
Journal:  J Clin Immunol       Date:  2012-02-29       Impact factor: 8.317

3.  Immunomodulatory Effect of Toll-Like Receptor-3 Ligand Poly I:C on Cortical Spreading Depression.

Authors:  Amir Ghaemi; Azadeh Sajadian; Babak Khodaie; Ahmad Ali Lotfinia; Mahmoud Lotfinia; Afsaneh Aghabarari; Maryam Khaleghi Ghadiri; Sven Meuth; Ali Gorji
Journal:  Mol Neurobiol       Date:  2014-11-23       Impact factor: 5.590

4.  Overexpression of programmed cell death ligand 1 in patients with CIN and its correlation with human papillomavirus infection and CIN persistence.

Authors:  Ceyda Sancakli Usta; Eren Altun; Selim Afsar; Cagla Bahar Bulbul; Akin Usta; Ertan Adalı
Journal:  Infect Agent Cancer       Date:  2020-07-17       Impact factor: 2.965

5.  Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia.

Authors:  Wen Yang; Yan Song; Yun-Long Lu; Jun-Zhong Sun; Hong-Wei Wang
Journal:  Immunology       Date:  2013-08       Impact factor: 7.397

6.  Vaccination Strategies for the Control and Treatment of HPV Infection and HPV-Associated Cancer.

Authors:  Emily Farmer; Max A Cheng; Chien-Fu Hung; T-C Wu
Journal:  Recent Results Cancer Res       Date:  2021

7.  RNA interference for the treatment of papillomavirus disease.

Authors:  Richa Singhania; Norliana Khairuddin; Daniel Clarke; Nigel Aj McMillan
Journal:  Open Virol J       Date:  2012-12-28

Review 8.  Role of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune response.

Authors:  Alfredo Amador-Molina; José Fernando Hernández-Valencia; Edmundo Lamoyi; Adriana Contreras-Paredes; Marcela Lizano
Journal:  Viruses       Date:  2013-10-28       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.